Castration-Resistant Prostate Cancer

Inclusion Criteria

- Male patients aged 18 years or older with histologically confirmed adenocarcinoma of the prostate
                - Patients who successfully completed 12 weeks of treatment according to study protocol 3104001 (NCT01317641; Bayer 17829) without any serious drug-related adverse events or dose-limiting toxicities
                - Patient was expected to benefit from participation in the study in the opinion of the investigator
                - Patients with any response or stable disease in Study 3104001 at week 12

Exclusion Criteria

- Patients who received prior therapy with MDV3100 or any investigational androgen receptor antagonist
                - Patients who received chemotherapy, radiotherapy or any experimental therapy within 4 weeks (within 6 weeks for nitrosoureas and mitomycin C) of the start of study treatment or had not recovered to Grade ≤1 or returned to baseline from any acute treatment-related toxicities of the previous therapy except for alopecia and Grade 2 neuropathy
                - Therapy with oral ketoconazole or CYP17 inhibitor within 30 days prior to the start of study treatment